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HIV-1 capsid uncoating initiates after the 
first strand transfer of reverse transcription
Ophélie Cosnefroy1, Philip J. Murray2 and Kate N. Bishop1*
Abstract 
Background: Correct disassembly of the HIV-1 capsid shell, called uncoating, is increasingly recognised as central for 
multiple steps during retroviral replication. However, the timing, localisation and mechanism of uncoating are poorly 
understood and progress in this area is hampered by difficulties in measuring the process. Previous work suggested 
that uncoating occurs soon after entry of the viral core into the cell, but recent studies report later uncoating, at or in 
the nucleus. Furthermore, inhibiting reverse transcription delays uncoating, linking these processes.
Results: Here, we have used a combined approach of experimental interrogation of viral mutants and mathemati-
cal modelling to investigate the timing of uncoating with respect to reverse transcription. By developing a minimal, 
testable, model and employing multiple uncoating assays to overcome the disadvantages of each single assay, we 
find that uncoating is not concomitant with the initiation of reverse transcription. Instead, uncoating appears to be 
triggered once reverse transcription reaches a certain stage, namely shortly after first strand transfer.
Conclusions: Using multiple approaches, we have identified a point during reverse transcription that induces 
uncoating of the HIV-1 CA shell. We propose that uncoating initiates after the first strand transfer of reverse 
transcription.
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Background
Following maturation and cleavage of the HIV-1 Gag 
polyprotein, capsid (CA) forms a highly ordered hexa-
meric lattice that generates a fullerene cone encasing 
the viral genome and associated proteins, known as the 
viral core [1–3]. This is released into the cytoplasm upon 
HIV-1 infection and the viral RNA is reverse transcribed 
by HIV-1 reverse transcriptase (RT) into double stranded 
DNA that is integrated into the host cell genome. As the 
outer face of the core, CA is likely involved in traffick-
ing the core to the nucleus [4] and protecting the viral 
nucleic acid from cytosolic sensors [5, 6]. However, the 
CA lattice can be recognised by cellular restriction fac-
tors that inhibit replication [7]. An intact viral core is 
thought too large to enter the nucleus via a nuclear pore 
and thus, shedding of the CA shell is an essential part of 
the retroviral life cycle, and is termed uncoating [8]. The 
mechanism of uncoating, when and where in the cell it 
occurs, and which, if any, host proteins contribute to the 
process are still largely unknown.
Originally, uncoating was believed to be a passive pro-
cess that started once the viral envelope was removed. 
More recently, inhibiting reverse transcription was 
reported to delay uncoating [9, 10]. Microtubule-facili-
tated uncoating has also been proposed [11, 12]. Other 
groups have suggested that the core must reach the 
nucleus to uncoat [13, 14], implying that uncoating fol-
lows reverse transcription. Regardless of timing, these 
findings concur that uncoating is a regulated process 
requiring a trigger. Indeed, perturbing uncoating is det-
rimental to viral infectivity [5, 15, 16] and therefore may 
represent a novel therapeutic target. Identifying what 
initiates uncoating is critical to understanding the role of 
CA and uncoating in HIV-1 replication.
HIV-1 replication can be followed by measuring the 
progress of reverse transcription. Reverse transcription is 
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a complex process, requiring the polymerase and RNase 
H enzymatic activities of RT along with two strand 
transfer events [17]. Here, we set out to investigate how 
uncoating is linked to reverse transcription. As there is no 
definitive assay to measure uncoating, we used a variety 
of techniques, including all existing uncoating assays and 
mathematical modelling. We established a simple, kinetic 
model of reverse transcription and uncoating based on a 
minimal set of assumptions. This enabled us to formu-
late and test alternative hypotheses, monitor consistency 
between data sets and make predictions that confirmed 
our experimental studies using HIV-1 mutants. Ulti-
mately, we propose that uncoating is triggered following 
the first strand transfer of reverse transcription.
Results
Nevirapine treatment inhibits uncoating
To confirm that uncoating is linked to reverse transcrip-
tion, we performed experiments to perturb reverse tran-
scription and measure uncoating. To do this, we utilised 
the non-nucleoside RT inhibitor nevirapine (NVP) to 
modulate reverse transcription, and took advantage 
of the ability of TRIMCyp to bind the HIV-1 capsid 
shell and inhibit replication [18] to indirectly measure 
uncoating using a previously published cyclosporine A 
(CsA) washout assay [9]. HIV-1 particles are only sensi-
tive to TRIMCyp inhibition until they have sufficiently 
uncoated [9, 18–21]. Furthermore, introducing CsA into 
cells blocks the interaction between TRIMCyp and CA, 
thus allowing replication to proceed in the presence of 
TRIMCyp. This can be used to measure uncoating by 
infecting OMK cells that contain endogenous TRIMCyp 
in the presence of CsA, and then measuring the abil-
ity of TRIMCyp to recognise the CA shell and restrict 
infection at various times post-infection by removing the 
CsA [9]. Figure 1a shows the effect on TRIMCyp restric-
tion of adding different concentrations of NVP for the 
first two hours of infection. We observed that: (1) more 
cells were infected the later CsA was removed from the 
media presumably as more particles uncoat with time, as 
previously reported [9] and (2) NVP treatment increased 
the length of time that virus particles were sensitive to 
TRIMCyp in a dose-dependent manner. Further experi-
ments were then performed varying the time of addition 
of 10  μM NVP (Fig.  1d). NVP was added for 4  h start-
ing at 0, 1 or 2 h post-infection. This additionally showed 
that (3) delayed NVP treatment appeared to temporarily 
pause uncoating until NVP was removed and (4) recov-
ery after NVP washout was incomplete. Viral cDNA was 
isolated from parallel infections following the same NVP 
treatments and quantified using qPCR (see Table  1 for 
products measured and primers used). This showed that 
synthesis of both early (−sscDNA) and late ((+)strand 
cDNA) were affected by the presence of NVP, as expected 
(Fig. 1b, c, e, f ). There was a dose-dependent decrease in 
the amount of cDNA products produced, with a larger 
effect on late cDNA production (Fig. 1b, c). Delayed NVP 
addition also showed that the later the drug was added, 
the more cDNA synthesis occurred (Fig. 1e, f ), although 
the block to reverse transcription continued even after 
NVP was removed from the media. Interestingly, the sen-
sitivity to TRIMCyp in the CsA washout assay reflected 
the levels of viral cDNA suggesting that the two events 
were linked. However, from these analyses, it is difficult 
to assess which aspect of reverse transcription leads to 
uncoating. For example, uncoating may be triggered by 
the initiation of reverse transcription or by the comple-
tion of cDNA synthesis. Therefore, to address whether 
uncoating is concurrent with reverse transcription or if 
it begins once reverse transcription has reached a certain 
point, we measured the effect on uncoating of blocking 
reverse transcription at various times.
Blocking RNase H activity inhibits uncoating
First, we investigated whether uncoating begins early, 
before the synthesis of −sscDNA, by studying HIV-1 VLP 
carrying mutations in RT [22–26]. The A114V catalytic 
domain mutation inhibits polymerase activity of RT [24] 
while mutations E478Q and H539F induce a complete 
reduction or a 50 % decrease in RNase H activity in vitro 
respectively [23]. Equal p24 units of VLP were used to 
challenge 293T cells and the percentage of infected cells 
was measured 72 h post-infection (h.p.i.) by flow cytom-
etry. All mutations reduced VLP infectivity to back-
ground levels (Fig. 2a). DNA was purified from infected 
cells at various times post-infection and the levels of early 
and late cDNA products were measured by qPCR. VLP 
carrying the A114V mutation failed to synthesise even 
−sscDNA, whilst the RNase H mutants were compe-
tent to synthesise early but not late cDNA (Fig. 2b), with 
E478Q more compromised than H539F. As these VLP 
were not infectious, we were unable to test the effects of 
these mutations on uncoating in the CsA washout assay. 
Instead, to investigate uncoating in a variety of ways and 
to limit the shortcomings of each, we performed four 
previously published assays; an in vitro core disassembly 
assay [15], a “fate-of-CA” assay [27], an in situ uncoating 
assay [28] and a TRIM5α abrogation assay [29]. In addi-
tion, these assays utilise multiple cell lines, removing any 
bias that may occur in any individual line.
First, for the in  vitro core disassembly assay, isolated 
viral cores were incubated with dNTPs for various times 
to allow reverse transcription to occur. Soluble CA was 
then separated from core-associated CA by centrifuga-
tion through a sucrose cushion and the fractions were 
analysed by immunoblotting and densitometry. The 
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percentage of CA in the pellet fraction was calculated and 
plotted (Additional file 1: Fig. S1). After 2 h, 50 % of the 
CA was detected in the pelletable fraction for all viruses, 
indicating that there was no difference in core disassem-
bly of the mutants in vitro. To assess uncoating in vivo, 
we first used a fate-of-capsid assay. HeLa cells infected 
with WT HIV-1 or RT mutants were lysed after 2 or 20 h 
and CA complexes in the cell lysate were separated from 
soluble CA by centrifugation through a sucrose cush-
ion (Additional file 1: Fig. S1). The percentage of CA in 
the pelletable fraction was calculated as a measure of 
the degree of uncoating that had occurred. Figure  2c 
shows that 20  h.p.i., only 25  % of CA in WT infections 
was pelletable, but 50 % of the CA from A114V or E478Q 
mutant VLP and ~35  % of CA from H539F was in the 
pellet fraction. Therefore, the amount of CA in the pellet 
inversely correlated with the amount of late cDNA prod-
ucts synthesised by each mutant (Fig. 2b). We next per-
formed an in situ uncoating assay [28]. HIV-1 VLP were 
labelled with two fluorescent proteins: GFP-Vpr to follow 
viral cores, and S15-mCherry to identify viral membranes 
[30]. This allows discrimination of particles that have suc-
cessfully fused with cell membranes from those that have 
not yet entered the cytoplasm. Bafilomycin A (Baf A) 
was added to one sample as a negative control for fusion. 
Following synchronised infections, cells were fixed and 
stained for CA at the indicated times and imaged. GFP, 
mCherry and CA puncta were identified and overlayed 
Fig. 1 Effect of NVP on cDNA synthesis and uncoating. a CsA washout assay. OMK cells were infected with GFP-HIV VLP in the presence of CsA and 
increasing concentrations of NVP. CsA was removed from each sample at the indicated time and NVP was removed from all samples 2 h.p.i. After 
72 h, the percentage of GFP positive cells was measured for each sample and plotted relative to the percentage of GFP positive cells following 
infection in the absence of NVP when CsA was removed 4 h.p.i. b, c 293T cells were infected with GFP-HIV VLP in the presence of increasing concen-
trations of NVP. NVP was removed from the media after 2 h. At the indicated times post-infection, the level of cDNA corresponding to  
a early (−sscDNA) or b late ((+)strand) reverse transcription products were analysed by qPCR. d CsA washout assay as in (a), except that 10 μM NVP 
was added for 4 h starting at 0, 1 or 2 h.p.i. The percentage of GFP positive cells for each sample was plotted relative to the percentage of GFP posi-
tive cells following infection in the absence of NVP when CsA was removed 7 h.p.i. e, f 293T cells were infected with GFP-HIV VLP in the presence 
of 10 μM NVP for 4 h starting at 0, 1 or 2 hp.i. Early (e) and late (f) cDNA was analysed by qPCR. Each panel shows the mean and SEM of at least 3 
independent experiments
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(Additional file  1: Fig. S1). All GFP positive, mCherry 
negative puncta were then classified as either CA positive 
(coated) or negative (uncoated) and the percentage of CA 
positive particles was quantified (Fig. 2d). The percentage 
of CA positive particles decreased with time for all infec-
tions but was most pronounced in WT infections where 
only 40 % of GFP positive particles were associated with 
CA after 2 h. The percentage of CA positive particles for 
all the RT mutants was similar to WT infections in the 
presence of either NVP or Baf A, suggesting that uncoat-
ing was similarly delayed for all of these mutants. Finally, 
we performed a TRIM5α restriction abrogation assay 
[29]. TRIM5α, like TRIMCyp, restricts incoming virions 
by binding to their CA shells [18], but lower endogenous 
expression levels compared to TRIMCyp enable high 
viral titres to saturate the protein and abrogate restric-
tion. Once a virion has lost its CA shell, TRIM5α cannot 
bind, so uncoated particles cannot abrogate restriction. 
Vero cells expressing endogenous TRIM5α were infected 
with serial dilutions of WT or RT mutant LacZ-encod-
ing HIV-1 VLP before being challenged with a fixed 
titre of WT GFP-encoding HIV-1 VLP. The number of 
cells expressing GFP was measured by flow cytometry 
after 48 h (Fig. 2e). Prior exposure of cells to the A114 V 
mutant VLP enhanced the GFP-encoding HIV-1 infec-
tivity by 200 % compared to prior exposure to WT VLP, 
suggesting that the mutant VLP were better at saturat-
ing TRIM5α. Prior exposure to either RNase H mutant 
also enhanced the GFP-HIV-1 infectivity compared to 
WT, by 150 %. In summary, using four different uncoat-
ing assays, we observed that inhibiting RNAse H func-
tion stabilised the CA shell of HIV-1 particles, apparently 
delaying or preventing uncoating. Therefore, although 
blocking reverse transcription inhibits uncoating, early 
DNA synthesis can occur without triggering the uncoat-
ing process.
Uncoating is not dependent on late products of reverse 
transcription
As it appeared that initiation of reverse transcription 
was not sufficient to induce uncoating, we then tested 
whether completion of reverse transcription was the trig-
ger for uncoating. We compared the rates of uncoating 
for VLP with different sized genomes. The genomes were 
identical except that one coded for GFP and the other 
for LacZ, making them 4457 or 6964 base pairs long 
respectively (Fig. 3a). Although early reverse transcripts 
were produced at similar rates for the two particles 
(Fig. 3b), there was a delay in the accumulation of late (+)
strand products for VLP containing the longer genomes 
(Fig. 3c). However, there was no difference in the rate of 
uncoating for these particles, as measured by the CsA 
washout assay (Fig. 3d) or a modified fate-of-capsid assay 
where infected cell lysates were separated in 10–50  % 
(w/w) sucrose gradients to assay for even small changes 
in CA complex size (Fig. 3e). This suggests that uncoating 
is independent of the length of the final cDNA product 
and the time taken to complete (−)strand synthesis.
First strand transfer is required for uncoating
Our experimental data therefore suggest that uncoating is 
initiated after RNaseH degradation of RNA following −
sscDNA synthesis but before second strand transfer. Four 
steps occur between these stages of reverse transcrip-
tion: First strand transfer, first strand elongation, RNase 
H degradation and initiation of (+)strand synthesis. 
To assess whether first strand transfer was required for 
uncoating, we designed two viral mutants to be defective 
Table 1 Real-time PCR primers and probes
a The expected length of the corresponding reverse transcribed DNA is indicated in brackets
Early: Strong stop cDNA (-sscDNA) (137 bases)a
Forward primer oHC64 5′-TAACTAGGGAACCCACTGC
Reverse primer oHC65 5′-GCTAGAGATTTTCCACACTG
Probe oHC66 5′-FAM-ACACAACAGACGGGCACACACTA-TAMRA
EGFP (1426 bases)a
Forward primer EGFP.F 5′-GCGCACCATCTTCTTCAAGG
Reverse primer EGFP.R 5′-GTGTCGCCCTCGAACTTCAC
Probe EGFP.Probe 5′-FAM-CGGCAACTACAAGACCCGCGC-TAMRA
Late: Second strand transfer ((+)strand) (3958 bases)a
Forward primer oHC64 5′-TAACTAGGGAACCCACTGC
Reverse primer GagM661as 5′-CTGCGTCGAGAGAGCTCCTCTGGTT
Probe oHC66 5′-FAM-ACACAACAGACGGGCACACACTA-TAMRA
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at this step (Fig.  4a). First, we synthesised an HIV-1 
genome with a chimeric 3′LTR (pCSGW-LTR Chimera) 
by replacing the R-U5 region from the HIV-1 3′LTR with 
that of MLV, to retain transcription signals whilst remov-
ing repeat signals. Secondly, we removed U3 and part of R 
from pCSGW-LTR Chimera to create pCSGW-LTR Del. 
As expected, both mutants had severely impaired infec-
tivity in single cycle infectivity assays (Fig. 4b) but were 
able to generate −sscDNA as well as WT VLP (Fig. 4c). 
Therefore, these mutations did not affect particle forma-
tion or initiation of reverse transcription. Surprisingly, 
the LTR chimera mutant was able to undergo first strand 
transfer and generate longer (−)strand transcripts cod-
ing for GFP, albeit not as efficiently as WT VLP (Fig. 4c). 
However, the levels of late cDNA were over 1000 times 
lower than in cells infected with WT VLP (Fig. 4c) sug-
gesting that cumulatively, strand transfer was impaired in 
this mutant. First strand transfer was strongly inhibited 
in the LTR Del mutant (Fig.  4c). We then assessed the 
effect of these mutations on uncoating.
In the fate-of-CA assay (Additional file 2: Fig. S2; Fig. 4d), 
the percentage of pelletable CA was increased 150–200 % in 
cells infected with the LTR mutants compared to WT VLP, 
similar to the RT A114V mutant. Likewise, in the in  situ 
uncoating assay (Fig. 4e), uncoating was delayed for both the 
LTR mutants compared to WT VLP, although the delay was 
not as great as seen with the RT A114V or RNase H mutants 
(Fig. 2d). Finally, in the TRIM5α restriction abrogation assay 
Fig. 2 Effect of RT mutations on infectivity, reverse transcription 
and uncoating. a, b, c 293T cells were infected with either WT (black) 
GFP-HIV VLP or VLP carrying mutations in RT at A114V (purple), E478Q 
(green) or H539F (blue). a The percentage of GFP positive cells was 
measured by flow cytometry 72 h.p.i. with increasing amounts of VLP, 
and plotted relative to the number of cells infected by 100 μl WT VLP. 
b The levels of early and late cDNA were detected by qPCR 6 h.p.i. c 
Fate-of-CA assay. HeLa cells were infected with WT or RT mutant GFP-
HIV VLP. Cells were lysed 2 or 20 h.p.i. and lysate separated into solu-
ble and pellet fractions by centrifugation through a sucrose cushion. 
CA was detected by immunoblotting, quantified and the percentage 
of total CA in the pellet fraction is plotted. d In situ uncoating assay. 
HeLa cells were infected with dual-labeled WT or RT mutant HIV VLP 
in the presence (orange) or absence of 10 µM NVP and then fixed 
and stained for CA at the indicated times post-infection. Baf A (red 
cirle) was added to one sample as a negative control for fusion. The 
percentage of fused particles that still stain for CA was calculated 1, 
2, or 4 h post-infection. e Saturation assay. Vero cells were infected 
with 2 fold serial dilutions of freshly harvested 293T cell supernatants 
containing WT or RT mutant LacZ-HIV VLPs. After 4 h, cultures were 
challenged with a fixed titre of WT GFP-HIV VLP. The percentage of 
GFP positive cells 72 h later is plotted relative to the infection seen 
following pre-infection with undiluted WT LacZ-HIV VLP. Each panel 
shows the mean and SEM of >3 independent experiments
▸
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(Fig. 4f), prior exposure of vero cells to the LTR-Del mutant 
enhanced the infectivity of the HIV-1 reporter VLP by 200 % 
compared to WT VLP, similar to the RT A114V mutant, 
suggesting that this mutant is better at saturating TRIM5α 
than WT VLP. However, prior exposure to the LTR-chimera 
mutant did not markedly enhance reporter VLP infectivity 
(Fig. 4f). The assay was validated by showing that the P38A 
CA mutant previously reported to uncoat more rapidly than 
WT VLP [15] was unable to enhance reporter VLP infectiv-
ity as well as WT VLP (Fig. 4f). Taken together, these results 
suggest that blocking first strand transfer (mutant LTR-del) 
leads to delayed uncoating. Reducing first strand transfer 
(mutant LTR-chimera) delays uncoating in the in situ assay 
but only has a mild effect on TRIM5α abrogation. This 
implies that the trigger for uncoating is after first strand 
transfer. Experimentally, it is problematic to be more precise 
than this, as it is difficult to individually block first strand 
elongation or (+)strand synthesis. Therefore, we decided to 
develop a mathematical model to independently define the 
point of reverse transcription that triggers uncoating.
Developing a mathematical model for reverse transcription
In order to develop a quantitative understanding of the 
kinetics of uncoating in relation to the kinetics of reverse 
transcription, we used the experimental observations 
from our CsA washout assays to parameterise a math-
ematical model and infer the putative position of an 
uncoating threshold. As our conclusions about the tim-
ing of uncoating did not incorporate these data and were 
based only on the results of our experiments using viral 
mutants, the modelling would therefore represent an 
independent assessment of the uncoating process.
We developed a six state mathematical model (Fig.  5) 
that describes particle progression through reverse 
transcription. The states in the model represent various 
sequential reverse transcription landmarks, from initia-
tion through to completion and are defined as follows: 
in State 1, particles are not yet transcriptionally active; 
in State 2, particles have initiated reverse transcription 
but not yet reverse transcribed −sscDNA (δ1 = 0 bases) ; 
in State 3, particles have reverse transcribed −sscDNA 
Fig. 3 Effect of viral RNA length on reverse transcription and uncoat-
ing. a Schematic representation of pCSGW and pHIVLacZ plasmids 
highlighting key positions in bp. b, c 293T cells were infected with 
either WT GFP-HIV (green) or LacZ-HIV (red) VLP. At the indicated times 
post-infection, the level of cDNA corresponding to b early or c late 
reverse transcription products were analysed by qPCR. d CsA wash-
out assay. OMK cells were infected with GFP-HIV or LacZ-HIV VLP in 
the presence of CsA. CsA was removed from each sample at the indi-
cated times. Infection was measured after 72 h and plotted relative to 
that observed when CsA was removed 4 h.p.i. e Modified fate-of-CA 
assay. 293T cells were infected with GFP-HIV or LacZ-HIV VLP. Cells 
were lysed 4 h.p.i. and lysate separated in a 10–50 % (w/v) sucrose 
gradient. The gel shows a representative image from 3 biological 
repeats. The CA content in each fractions was detected by immuno-
blotting, quantified and the percentage of CA relative to the total cell 
lysate (input) was calculated and plotted. Each graphical panel shows 
the mean and SEM of at least 3 independent experiments
◂
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but not yet undergone second strand transfer (δ2 = 137 
bases); in State 4, particles have completed second 
strand transfer but not yet finished reverse transcription 
(δ3 = 3958 bases) and in State 5, transcription is com-
plete (δ4 = 8912 bases).
To infer a putative position beyond which TRIMCyp 
loses efficacy, we introduced state U at an arbitrary posi-
tion along the viral genome (δ1 < bp∗ < δ4) such that 
upon CsA removal, all particles in preceding states are 
immediately degraded. Qualitatively, we defined three 
alternative hypotheses for the timing of uncoating: (1) 
early (δ1 < bp∗ < δ2), (2) intermediate (δ2 < bp∗ < δ3) 
and (3) late (δ3 < bp∗ < δ4). For brevity, in the presenta-
tion of Fig. 5 and in the model equations below, we only 
show the outcome of uncoating occurring between the 
transcription of -sscDNA (State 3) and second strand 
transfer (State 4).
We assume that initiation of reverse transcription 
from a latent pool occurs at rate k1 and transition rates 
between subsequent states are defined by the parameter 
Fig. 4 Effect of FST mutations on infectivity, reverse transcription and uncoating. a Schematic representation of FST mutants. b, c 293T cells were 
infected with either WT (black) GFP-HIV VLP, VLP carrying a chimeric (blue) or partially deleted (green) 3′LTR. b The percentage of GFP positive cells 
was measured by flow cytometry 72 h.p.i. with increasing amounts of VLP, and plotted relative to the number of cells infected by 100 μl WT VLP.  
c The levels of early, intermediate (GFP gene) and late cDNA were detected by qPCR 6 h.p.i. d Fate-of-CA assay. HeLa cells were infected with either 
WT (black) GFP-HIV VLP or VLP carrying the RT mutation A114V (purple), a chimeric 3′LTR (blue) or partially deleted 3′LTR (green). Cells were lysed 
20 h.p.i. and lysate separated into soluble and pellet fractions by centrifugation through a sucrose cushion. CA was detected by immunoblotting, 
quantified and the percentage of total CA in the pellet fraction plotted. e In situ uncoating assay. HeLa cells were infected with dual-labeled WT 
or mutant HIV VLP and then fixed and stained for CA at the indicated times post-infection. Baf A (red circle) was added to one sample as a negative 
control for fusion. The percentage of fused particles that still stain for CA was calculated 1, 2, or 4 h.p.i. f Saturation assay. Vero cells were infected 
with 2 fold serial dilutions of freshly harvested 293T cell supernatants containing WT, mutant GFP-HIV VLPs or P38A capsid mutant GFP-HIV VLP 
(orange). After 4 h, cultures were challenged with a fixed titre of WT LacZ-HIV VLP. The level of β-galactosidase activity in cell lysates was measured 
after 72 h and is plotted relative to the level of infection seen following pre-infection with undiluted WT GFP-HIV VLP. Each panel shows the mean 
and SEM of at least 3 independent experiments
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ki. Once reverse transcription has initiated, we assume 
that the average time spent in each state is proportional 
to the number of base pairs that need to be transcribed to 
progress, i.e. the transition rates satisfy
where tbp is the average time taken for a particle to reverse 
transcribe one base pair and δ = [δ1, δ2, bp∗, δ3, δ4].
To account for the intrinsic degradation of coated 
particles that occurs in host cells, we assume that in the 
absence of TRIMCyp, degradation occurs at background 
rate kdeg and that in the presence of TRIMCyp degrada-
tion is concomitant with CA binding and instantaneous. 
As viral infectivity assays at different NVP concentra-
tions yielded a value for the I0 constant KNVP of 0.1 μM, 
in agreement with previous studies [31], we assumed an 
inverse dependence of reverse transcription rate param-
eters on NVP, i.e.
where NVP(t) is specified in a given experiment. The 
complete model equations are given by
with initial conditions representing the case of no initial 
reverse transcription products, i.e.
To identify the four unknown model parameters, we 
used the data presented in Fig.  1c–f, where a series of 
experiments were performed that measured variables 
that are directly comparable with quantities described 
by the model. The −sscDNA and (+)strand products of 
reverse transcription were measured following different 
treatments with the reverse transcription inhibitor Nevi-
rapine, and viral infectivity was measured against various 
backgrounds of Nevirapine and CSA.
ki =
ln (2)
tbp(δ[i]− δ[i − 1]).
, i > 1,
(1)g(NVP(t)) =
1
1+
NVP(t)
KNVP
,
(2)
dN1
dt
= −k1N1,
dN2
dt
= k1N1 − k2g(NVP(t))N2 − kdegN2,
dN3
dt
= k2g(NVP(t))N2 − k3g(NVP(t))N3 − kdegN3,
dNU
dt
= k3g(NVP(t))N3 − k4g(NVP(t))NU ,
dN4
dt
= k4g(NVP(t))NU − k5g(NVP(t))N4,
dN5
dt
= k5g(NVP(t))N4,
N1(0) = 100; Ni(0) = 0, i > 1.
Using Bayesian inference, we identified regions of 
parameter space that best fit the experimental data (see 
Fig.  6 for best fit solutions and Fig.  7a–e for parameter 
robustness estimates). The value of k1 that best fits the 
data is 0.29± 0.02 h−1. The value of tbp, the average time 
taken to transcribe one base pair, is 2.4 ± 0.37× 10−4 h , 
a value that is similar to previously reported values. We 
find that the parameter kdeg is 0.3± 0.06 h−1, suggest-
ing that even in the presence of CSA, the half life of 
particles is of the order of 2 h. Finally, we estimate that 
bp∗ = 974 ± 326 bases (errors represent 95  % credible 
intervals). Within our GFP vector, the uncoating thresh-
old is reached on the negative strand just before the 
sequence coding for GFP, while in the HIV-1 complete 
genome it corresponds to the sequence ~50 bp upstream 
of the Nef coding region, which is ~10 % along the total 
transcribed genome. Therefore, as uncoating must be 
triggered before State U, it is likely to start soon after 
first strand transfer, as (−)strand cDNA extends or, per-
haps more likely, as (+)strand synthesis initiates and cre-
ates a short section of double stranded (ds)DNA. Using 
the fitted parameters to calculate the average time spent 
in state 1 (2.35  h), and adding to this the time taken to 
reverse transcribe the 1000 bases necessary to get to the 
threshold (0.24  h), our model kinetics estimate uncoat-
ing to occur 2.6± 0.13 h.p.i. (Fig.  7f ). This is similar to 
recent reports of the timing of uncoating [21]. Finally, 
to independently test the fitted model, we performed 
additional CsA washout experiments in which NVP was 
applied for 2 h windows, and compared the model fits to 
experimental data (Fig.  7g). The calculated Chi squared 
measurements show that the model was able to satisfac-
torily predict the experimental outcomes, leading us to 
conclude that the predicted timing of uncoating was a 
reasonable estimation.
In summary, by fitting the model to infectivity data 
from CsA washout experiments carried out under a 
range of NVP concentrations, we predict that virus is 
sensitive to TRIMCyp until some time after the tran-
scription of -sscDNA. This is in excellent agreement with 
our conclusions from experiments with viral mutants 
in which we blocked specific steps of reverse transcrip-
tion. In turn, this suggests that uncoating is not triggered 
merely by the initiation of reverse transcription, and also 
lends support to the idea that late reverse transcription 
occurs after uncoating has begun.
Discussion
Understanding the timing and triggers for uncoat-
ing has become central to investigations of all aspects 
of the early stages of retroviral replication. Here, we 
sought to identify the point of reverse transcription 
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that initiates the uncoating process to determine how 
reverse transcription and uncoating are linked. We gen-
erated experimental data using various viral mutants to 
inhibit reverse transcription at several specific points, 
and also developed and parameterised a mathematical 
model for reverse transcription that could investigate the 
effect of NVP on uncoating in a CsA washout assay. Both 
approaches came to similar conclusions.
Fig. 5 Schematic illustration of the mathematical model. Top shows a schematic representation of the pCSGW plasmid highlighting the position 
of primers used for the qPCR. Bottom illustrates the proposed six-state model of reverse transcription highlighting the effects of NVP and CsA. The 
lengths of the reverse transcribed cDNA corresponding to each state are indicated on the right
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Fig. 6 Modelling HIV-1 uncoating relative to reverse transcription. For each panel, points represent experimental data and solid lines indicate model 
solutions. a, b 293T cells were infected with GFP-HIV VLP in the presence of 10 μM NVP for 4 h starting at 0, 1 or 2 h.p.i. Early (a) and late (b) cDNA 
was analysed by qPCR. c, d CsA washout assays. OMK cells were infected with GFP-HIV VLP in the presence of c 10 μM NVP for 4 h starting at 0, 1 or 
2 h.p.i. or d increasing concentrations of NVP for 0–2 h. CsA was removed from each sample at the indicated time. After 72 h the percentage of GFP 
positive cells was measured and plotted relative to the percentage of GFP positive cells following infection in the absence of NVP when CsA was 
removed 7 h.p.i. Each panel shows the mean and SD of at least 3 independent experiments. Model solutions were computed using Eq. (2) stated 
in the text and the best fit parameters k1 = 0.29 h
−1; tbp = 2.4× 10−4 h; kdeg = 0.3 h
−1; bp∗ = 974 bases. Other parameters were: KNVP = 0.1 μM, 
Ninit = 100, bp–sscDNA = 137; bp(+)strand = 3958
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As there is no definitive assay for CA uncoating, we 
tested the effects of our viral mutations on uncoat-
ing using a range of uncoating assays (Figs.  2, 4). Each 
assay has its limitations, for example, in vitro assays are 
performed in the absence of cellular factors that may 
contribute to the uncoating process. Furthermore, bio-
chemical and microscopic assays, such as the fate-of-CA 
and in  situ uncoating assay, monitor bulk populations 
of virus particles, many of which may be defective and 
may exhibit misleading behaviours. The timing of the 
measurements post-infection also affects the outcomes 
of these assays. Although the CsA washout assay has 
the advantage that it only measures the effects on parti-
cles that go on to form productive infections, it is indi-
rect and uses TRIMCyp restriction as a readout, which 
is itself poorly understood. It is not known how many 
CA molecules must be present on particles for TRIM-
Cyp to restrict infection, although as TRIMCyp binds 
capsid shells very soon after viral entry, it seems likely 
that the CsA washout assay measures the early stages 
Fig. 7 Robustness of parameter fitting and testing the mathematical model of uncoating. a–d Estimated marginal distributions were computed 
for each model parameter from the calculated posterior distribution. Best fit parameters were defined using median values of marginal distribution 
and presented with 95 % credible intervals in (e). f The time of uncoating, tuncoating was estimated using the best fit parameters. g Testing the model 
predictions of infection kinetics in the CsA washout assay. OMK cells were infected with GFP-HIV VLP in the presence of CsA and 10 μM NVP for 2 h 
starting at 0, 1 or 2 h.p.i. CsA was removed from each sample at the indicated time. After 72 h, the percentage of GFP positive cells was measured for 
each sample and plotted relative to the percentage of GFP positive cells following infection in the absence of NVP when CsA was removed 7 h.p.i. 
Points represent experimental data from two independent experiments and solid lines indicate model predictions
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of uncoating. Another disadvantage of this assay is that 
non-infectious mutants like our RNase H mutants can-
not be tested. For this reason, we repurposed a similar 
assay, the TRIM5α abrogation assay, to test capsid shell 
integrity in yet another way. However, despite the differ-
ences between all the assays used, the data from all our 
analyses were in general agreement, giving us conviction 
to conclude that uncoating is triggered by a mid point in 
reverse transcription, between the two strand transfers.
Experimentally, it is difficult to be more specific about 
the point at which uncoating is triggered as it is not pos-
sible to individually block first strand elongation or sec-
ond strand synthesis. However, using our mathematical 
model, derived from independent experimental data, 
we estimated the point of reverse transcription at which 
uncoating occurs. We introduced an additional state into 
the model to constrain the point at which TRIMCyp 
loses efficacy and determined, by minimising the error 
between model and experimental observations, that the 
optimal position for it was approximately 1000 bases 
along the viral genome (Fig.  7). Therefore, uncoating is 
likely to start at an early step after first strand transfer as 
it must be triggered before this additional state. As with 
the experimental data, the model has some limitations. 
Whilst it is in reasonable agreement with the infected cell 
data, it does not fully capture the qPCR measurements 
following NVP removal. The reason that the model over-
estimates the recovery of reverse transcription after NVP 
treatment is unclear and may reflect off-target effects of 
the drug or unaccounted for cellular influences on the 
virus.
The fact that both analysis of viral mutants and an inde-
pendent mathematical model suggest uncoating occurs at 
this stage of reverse transcription does, however, give us 
confidence in our conclusions. Specifically, we propose 
that uncoating is triggered either by elongation of the (−)
strand viral cDNA, or by initiation of (+)strand synthe-
sis to generate a dsDNA fragment. Either scenario would 
increase the bulk of DNA in the particle, and the more 
structured dsDNA may pack less efficiently inside the 
capsid shell. Therefore, uncoating could be caused by the 
increasing volume constraint on the capsid. Alterations 
in CA that influence the intrinsic stability of the shell or 
modulation of the interactions of cellular factors with 
CA could affect the resistance of the shell to such force, 
and affect the timing of uncoating [11, 12, 32]. This could 
result in the loss of some capsid without necessitating the 
loss of all of the capsid from the PIC, fitting with recent 
reports of a bimodal dissociation of CA [33, 34]. How-
ever, dsDNA might also be detected by a specific mecha-
nism leading to programmed uncoating. Interestingly, 
early access to the viral core is reportedly not affected by 
reverse transcription [34], although this did not correlate 
with overall CA shell stability or the major loss of CA.
Taken together with reports that CA may be present 
in the nucleus [33, 35] and influences nuclear replica-
tion steps such as integration [36, 37], we can perhaps 
consider the uncoating process in three phases: (1) Early 
opening of the CA lattice allowing entry of cellular fac-
tors such as dNTPs and other molecules required for 
reverse transcription. (2) The loss of the majority of CA 
and the integrity of the lattice. (3) The loss of the remain-
ing CA inside or at the nucleus. Phase one could be initi-
ated by entry of the viral core into the cytoplasm. Phase 
2 triggered during reverse transcription, and phase 3 
accomplished upon integration of the viral cDNA. There-
fore, the general term “uncoating” is probably most 
applicable to phase 2. Notably, loss of the majority of 
CA before completion of reverse transcription suggests 
that the CA shell alone is not responsible for protecting 
the viral DNA from innate immune sensing. However, if 
phase 2 of uncoating occurred at the nuclear periphery, 
then other factors may ‘cloak’ the viral DNA until reverse 
transcription is finished. Alternatively, reverse transcrip-
tion could be completed inside the nucleus. Further work 
is needed to elucidate the role of CA in nuclear import 
and integration, but it is clear that the timing of the bulk 
of CA loss is linked to replication of the viral genome.
Conclusions
HIV-1 CA uncoating is very difficult to study because it 
is a dynamic process and direct observation is obscured 
by the presence of non-infectious particles and issues 
with sensitivity of detection. However, it is important to 
understand the behaviour of the CA shell as it appears to 
be critical for several post-entry steps during replication. 
By combining experimental data from multiple uncoating 
assays with a novel mathematical model for uncoating, 
we aimed to identify the point in reverse transcription 
that triggers uncoating. We show here that uncoating is 
triggered following first strand transfer and propose that 
either elongation of the (−)strand viral cDNA, or initia-
tion of (+)strand synthesis is sufficient to start the break-
down of the HIV-1 CA shell.
Methods
Cells
293T, HeLa, OMK and VERO cells (authenticated, 
mycoplasma-free Bishop laboratory cell stocks) were 
maintained in Dulbecco’s modified Eagle medium (Inv-
itrogen) supplemented with 10 % heat-inactivated foetal 
bovine serum (Biosera) and 1 % Penicillin/Strepomycin/
Glutamine (Sigma). Cyclosporine A (CsA; Sigma) was 
prepared in DMSO at 300  μM, and used at a final 
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concentration of 3 μM. Nevirapine (NVP; National Insti-
tutes of Health (NIH) AIDS Research and Reference Rea-
gent Program) was prepared in ETOH at 1 mM and used 
at a final concentration of 0.1; 1 or 10 μM. Bafilomycine 
A1 (Sigma) was prepared in DMSO at 2 mM, and used at 
a final concentration of 20 nM.
Plasmids and cloning
HIV-1 VLP were produced by cotransfection of pVSV-G, 
pCMVΔ8.91 and either pCSGW or pWPTS-nlsLacZ [38]. 
The pCMVΔ8.91 construct expressing RT mutant A114V 
was gift from J. Stoye. To create the other mutant Gag-
Pol plasmids, site directed mutagenesis was performed 
on pCMVΔ8.91 using the Quik-Change kit (Stratagene) 
using the following primers; RNase H mutant E478Q: 
for 5′-CACAACAAATCAGAAGACTCAGTTACAAGCA 
ATTCATCTA and rev 5′-TAGATGAATTGCTTGTA 
ACTGAGTCTTCTGATTTGTTGTG; RNase H mutant 
H539F: for 5′-CCTGGCATGGGTACCAGCATTCAAAG 
GAATTGGAGGAAAT and rev 5′-ATTTCCTCCAATTC 
CTTTGAATGCTGGTACCCATGCCAGG; CA mutant 
P38A: for 5′-GGCTTTCAGCCCAGAAGTGATAGCCAT 
GTTTTCAGCATTA and rev 5′-TAATGCTGAAAAC 
ATGGCTATCACTTCTGGGCTGAAAGCC. The LTR 
Chimera strand transfer mutant was constructed by 
overlapping PCR from three DNA fragments amplified 
from either pCSGW (for HIV ΔU3 and flanked region) 
or pczLTR-LacZ (for Mo-MLV R-U5 [39]). All DNA 
fragments were amplified using Phusion DNA poly-
merase (Finnzymes) with the following primers: HIV 
ΔU3: for 5′-CGTCCCTTCGGCCCTCAATC and rev 
5′-CTATCGGAGGACTGGCGCCCAGTACAAGCAAAA 
AGC; Mo-MLV R-U5: for 5′-GCTTTTTGCTTG 
TACTGGGCGCCAGTCCTCCGATAG and rev 5′-CGG 
AATTAATTCTAGATGCGCTGACGGGTAGTCAATC; 
HIV-1 flanking region: for 5′-GATTGACTACCCGTCA 
GCGCATCTAGAATTAATTCCG rev 5′-GCACCATTCG 
ACGCTCTCCC. The final PCR fragments were amplified 
with primers for 5′-CGTCCCTTCGGCCCTCAATC and 
rev 5′-GCACCATTCGACGCTCTCCC, and inserted into 
pCSGW between the SacII and AfeI restriction sites. The 
MLV 3′LTR partial deletion mutant was synthesised by 
digestion of the LTR Chimera mutant with KpnI.
VLP production
HIV-1 VLP were synthesised by co-transfection of 293T 
cells with pCMVΔ8.91 (or mutants), VSV-G, and either 
pWPTS-nlsLacZ (for LacZ-expressing VLP) or WT or 
mutant pCSGW (for GFP-expressing VLP). After 24  h, 
cells were treated with 10  mM sodium butorate, and 
virus-containing supernatants were harvested 24 h later. 
For the in  situ uncoating assay, dual-labeled VLP were 
produced by transfecting a 4:4:4:4:1 ratio of pCMVΔ8.91 
(or mutants), pWPTS-nlsLacZ, VSV-G, pS15-mCherry 
and pGFP-VPR [30]. Virus-containing supernatants were 
harvested 24 h after transfection. All supernatants were 
purified through a 0.22-μM filter and titred using a p24 
ELISA assay (PerkinElmer).
Infectivity assay
293T cells were challenged with equivalent p24 units of 
GFP-HIV or LacZ-HIV VLP for 72 h. For GFP-VLP, the 
percentage of cells expressing GFP was determined by 
flow cytometry using a FACS VERSE analyser (Becton–
Dickinson). Cells infected with LacZ-VLP were lysed and 
β-galactosidase activity in cell lysates was measured using 
the Galacto-Star system (Applied Biosystems).
Quantitative PCR analysis
The quantitative PCR analysis was conducted as previ-
ously described [40]. Prior to infection, VLP were treated 
with 20 units/ml RQ1-DNase (Promega) in 10  mM 
MgCl2 for 1 h at 37  °C. 293T cells (2 ×  105) were spin-
oculated (1600×g at 16 °C for 30 min, followed by 37 °C 
for 30 min) and the media was replaced by warm DMEM. 
Cells were harvested at the indicated time point post-
infection and total DNA was extracted using the DNeasy 
Blood & Tissue Kit (Qiagen). After digestion with 1 unit/
μl DpnI for 1 h at 37 °C, 20 ng of DNA was analysed in 
triplicate (technical repeats) by qPCR using the iCy-
cler iQ real-time PCR detection system (BioRad) with 
900 nM primers and 250 nM probes (Table 1). The PCR 
reactions were performed on a Fast 7500 PCR system 
(Applied Biosystems) using standard cycling conditions: 
50 °C for 2 min, 95 °C for 10 min followed by 40 cycles of 
95 °C for 15 s and 60 °C for 1 min. Relative cDNA copy 
numbers were calculated using a standard curve gener-
ated from serial dilutions of pCSGW or pWPTS-nlsLacZ 
in 293T cellular DNA. Unless stated, graphs show the 
mean and SEM of at least 3 biological repeats.
CsA washout assay
The CsA washout assay was previously described [9]. 
OMK cells endogenously expressing TRIMCypA were 
seeded at 1 ×  105 cells per well in 24-well plates  1  day 
prior to infection. Cells were spinoculated (1600×g at 
16  °C for 1  h, followed by 37  °C for 30  min) with GFP 
or LacZ VLP in the presence of 3 μM CsA (Sigma) and 
5  μg/ml polybrene with or without NVP (NIH AIDS 
Research and Reference Reagent Program; 0.1, 1 or 
10  μM in EtOH). Inoculation media was exchanged for 
warm media containing CsA and/or NVP as appropri-
ate, and this was considered the zero time point. CsA 
was removed at the indicated times post-infection by 
media exchange. NVP was added to the warm media at 
the indicated times and removed from all reactions by 
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media exchange. Three days after infection, the percent-
age of GFP-positive cells was determined by flow cytom-
etry. For cells infected with LacZ-VLP, cells were lysed 
and β-galactosidase activity in cell lysates was measured 
using the Galacto-Star system (Applied Biosystems). 
Unless stated, graphs show the mean and SEM of at least 
3 biological repeats.
In vitro core disassembly assay
Core isolation and in  vitro disassembly were previ-
ously described [15]. VLP-containing supernatant from 
transfected 293T cells was concentrated through a 20 % 
(w/w) sucrose cushion at 32,000  rpm at 4  °C for 4  h in 
a Beckman SW32 rotor. Viral pellets were re-suspended 
in 250 μl PBS and centrifuged (28,500 rpm in a Beckman 
SW41 rotor at 4 °C for 16 h) through a layer of 1 % triton 
X-100 overlaying a 30 % (w/w) sucrose cushion to isolate 
viral cores. Core-containing pellets were re-suspended in 
300 μl of PBS and incubated at 37 °C with 1 mM dNTPs 
and 50 mM MgCl2. At the indicated times post-incuba-
tion, samples were removed and centrifuged (32,000 rpm 
in a Beckman SW55 rotor at 4 °C for 1 h) through a 30 % 
(w/w) sucrose cushion. The top layer above the sucrose 
cushion was collected as the “soluble” fraction and once 
the remaining sucrose was removed, SDS-PAGE loading 
dye was added to the tube to re-suspend the “pellet” frac-
tion. Fractions were analysed for CA protein content as 
in the fate-of- CA assay.
Fate-of-capsid assay
The fate-of-capsid assay was previously described 
[27]. HeLa cells were seeded at 106 cells/well in 6-well 
plates 1-day before infection and spinoculated (1600×g at 
16 °C for 30 min, followed by 37 °C for 1 h) with 1.5 mL/
well of concentrated GFP-VLP supernatant containing 
5 μg/ml polybrene. Inoculation media was then replaced 
with warm DMEM. Cells were harvested 2 or 20 h.p.i. and 
cells from 6 wells were pooled for each infection. Cells 
were washed in PBS and resuspended in 7  mg/ml pro-
nase (Sigma) before being pelleted and resuspended in 
700 μl hypotonic buffer (10 mM Tris–Cl pH 8.0, 10 mM 
KCl, 1 mM EDTA supplemented with complete protease 
inhibitors (Roche)). After incubation on ice for 15  min, 
cell suspensions were applied to a Qiashredder column 
(Qiagen) and centrifuged at 20,000×g for 2 min at 4  °C. 
Cell lysates were layered on top of either a 10–50 % (w/v) 
linear sucrose gradient or on top of 30 % (w/w) sucrose 
cushion and centrifuged at 32,000 rpm for 1 h at 4 °C in 
a Beckman SW41 rotor. An aliquot of the cell lysate was 
kept as an input control. Nine 500 μl fractions were col-
lected from the top to the bottom of the gradient using 
a syringe pump-driven gradient fractionator (Brandel). 
Proteins were extracted using methanol/chloroform and 
resuspended in SDS-PAGE loading dye. The top layer 
above the sucrose cushion was collected as the “soluble” 
fraction and once the remaining sucrose was removed, 
SDS-PAGE loading dye was added to the tube to re- sus-
pend the “pellet” fraction. Fractions were analysed for 
CA protein content by immunoblotting using a mouse 
monoclonal anti-HIV-1 CA antibody, 24-2 (a gift from 
Michael Malim) followed by rabbit anti-mouse HRP-
conjugated secondary antibody (Life Technologies Ltd). 
Detection was performed using the Immobilon chemilu-
minescent substrate (Millipore) and hyperfilm processed 
through a Fijifilm FPM-3800A developer. Quantification 
of band density was performed using Fiji software after 
scanning immunoblot on an HP Scanjet 3800.
In situ uncoating assay
The in situ uncoating assay was conducted as previously 
described [28]. At least two different preparations of each 
virus were used for each assay. HeLa cells were seeded at 
106 cells/well on 13 mm coverslips in 12-well plates 1-day 
before infection and were spinoculated (1600×g at 16 °C 
for 1  h) with dual-labelled VLP. Inoculation media was 
replaced by warm DMEM and at the indicated time 
points post-infection, cells were fixed in 4  % paraform-
aldehyde (ChemCruz) for 20  min at room temperature. 
Fixed cells were then permeabilized with 0.1 % triton-100 
for 10 min, washed with PBS, and blocked with 5 % nor-
mal donkey serum (NDS, Source Bioscience) for 1  h. 
Cells were then incubated in primary anti-CA antibody 
(p24 05-009, diluted 1/250 in 1  % NDS) overnight fol-
lowed by 2  h incubation with donkey anti-mouse sec-
ondary antibody coupled to Alexa Fluor647 (Invitrogen) 
diluted 1:500. Samples were washed with PBS, mounted 
on slides and dried. Images were acquired using a Delta 
Vision Deconvolution microscope (Olympus IX70) and 
SoftWorks software (Applied Precision). Ten images 
were analysed for each viral infection at each time point. 
All GFP-Vpr positive puncta over 15.8 μm were counted 
using CellProfiler software (http://www.cellprofiler.org) 
and scored as associated or not with S15-mCherry and/
or CA positive or negative. For each infection, the per-
centage of CA positive particles at the 0 h time point is 
the percentage of mCherry positive, CA positive, GFP 
positive puncta out of the total number of GFP positive 
puncta, and the percentage of CA positive particles at the 
remaining time points is the percentage of mCherry neg-
ative, CA positive, GFP positive puncta out of the total 
number mCherry negative, GFP positive puncta.
Saturation assay
TRIM5alpha saturation assays were conducted as previ-
ously described [29]. Vero cells expressing endogenous 
TRIM5alpha were seeded at 105 cells/well in 24-well 
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plates one day prior to infection. Cells were infected 
with 2 fold serial dilutions of freshly harvested 293T cell 
supernatants containing GFP or LacZ-encoding VLP. 
Cultures were incubated for 4–6 h at 37  °C before add-
ing a fixed amount of LacZ or GFP-encoding HIV-1 
respectively (equivalent to an MOI of 0.5 in 293T cells). 
After 72  h, infected cells were harvested and either the 
percentage of GFP-positive cells was determined by flow 
cytometry or β-galactosidase activity in cell lysates was 
measured using the Galacto-Star system as for infectivity 
assays.
Mathematical model
Matlab codes used to simulate the model can be found at 
https://github.com/murrayp/RTUncoatingModel.
Six state model
To compare the model with experimental measure-
ments, Eq.  (2) were solved numerically. The variable 
corresponding to measurable −sscDNA is given by the 
cumulant
that corresponding to (+)strand cDNA by the cumulant
and the number of infected cells to be
Parameter inference
We define the likelihood for the strong stop dataset to be
the likelihood for the second strand dataset to be
and the likelihood for the infected cell dataset to be
where M1 M2 and M3 represent different experiments, 
N1 N2 and N3 the number of time points, hatted variables 
ϕ3(t) = NU (t)+
5∑
i=3
Ni(t),
ϕ5(t) =
5∑
i=4
Ni(t),
ϕ∞ = N5(t →∞).
L1 =
M1∏
j=1
N1∏
i=1
e
−
(
ϕj3(i)−ϕ̂j3(i)
)2
σj3(i)
2
,
L2 =
M2∏
j=1
N2∏
i=1
e
−
(
ϕj5(i)−ϕ̂j5(i)
)2
σj5(i)
2
,
L3 =
M3∏
j=1
N3∏
i=1
e
−
(
ϕj∞(i)−ϕ̂j∞(i)
)2
σj∞(i)
2
,
represent corresponding experimental measurement and 
the σjs are sample standard deviations. The total likeli-
hood is defined to be L = L1L2L3.
We define uniform (uninformative) pri-
ors on the four unknown parameters 
(
U[0.05,0.5] ,
U[1×10−6,1×10−2],U[0,10000],U[1×10−4,0.8]
)
 and use slice 
sampling [41] to approximate the posterior distribution, 
given Baye’s Rule
where L(θ |k1tbpbp∗kdeg ) is the likelihood of the data, 
θ , P(x) represents prior probability distributions and 
P(k1tbpbp
∗kdeg |θ) represents the posterior distribution.
To assess goodness of fit we calculated the Chi squared 
statistic
In infected cell experiments in Fig.  2 (rows 3 and 4) 
there were only two measurements at each time point 
and the sample standard deviations from experiment 
in Fig.  2 (row 2) were used to compute Chi squared 
statistic.
P(k1tbpbp
∗kdeg |θ) = L(θ |k1tbpbp
∗kdeg )P(k1)P
(
tbp
)
P
(
bp∗
)
P
(
kdeg
)
,
χ2 =
1
N
N∑
i=1
(
ϕ(i)− ϕ̂(i)
)2/
σj(i)
2
Additional files
Additional file 1. Effect of RT mutations on capsid stability in vitro and 
on uncoating. (a,b) Isolated cores from either WT GFP-HIV VLP (black) or 
VLP carrying mutations in RT at A114 V (purple), E478Q (green) or H539F 
(blue) were incubated at 37 °C for 0, 1 or 2 h. Pelletable material was 
separated from soluble proteins by centrifugation through a sucrose 
cushion and CA was detected by immunoblotting. (a) A representa-
tive immunoblot from 3 independent experiments. (b) The CA bands in 
each immunoblot were quantified and the percentage of total CA in the 
pellet fraction was calculated. The graph shows the mean and SEM of 3 
independent experiments. (c) Immunoblot of a fate-of-CA assay. HeLa 
cells were infected with WT or RT mutant GFP-HIV VLP. Cells were lysed 
2 or 20 h.p.i. and lysate [input, I] separated into soluble [S] and pellet [P] 
fractions by centrifugation through a sucrose cushion. CA was detected 
by immunoblotting. Data is representative of 5 independent experi-
ments. (d) Confocal microscopy images from an in situ uncoating assay. 
Left: HeLa cells infected with dual-labelled WT HIV-1 VLP were imaged 
1 h.p.i. The outlined box is enlarged in the other three panels to show the 
distribution of S15-mCherry (red, denoting enveloped particles), Vpr-GFP 
(green, denoting viral cores), and CA (white). Fused virions are punctate 
spots that are GFP positive and mCherry negative, and were classified as 
associated with p24CA (horizontal arrows) or not associated with p24CA 
(vertical arrows).
Additional file 2. Effect of FST mutations on capsid stability. (a-b) HeLa 
cells were infected with WT GFP-HIV VLP, or VLP carrying LTR mutations 
(LTR Del or LTR Chimera). Cells were lysed (a) 2 h or (b) 20 h.p.i. and cell 
lysate [input, I] was separated into soluble [S] and pellet [P] fractions by 
centrifugation through a sucrose cushion. CA was detected by immunob-
lotting. Blots are representative of 3 independent experiments.
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